Patent: 9,605,064
✉ Email this page to a colleague
Summary for Patent: 9,605,064
Title: | Methods and compositions for treatment of skin disorders |
Abstract: | The invention provides methods and compositions for the treatment of a skin disorder associated with detrimental TNF.alpha. activity, such as psoriasis. The invention includes methods for treating a skin disorder associated with detrimental TNF.alpha. activity, such as psoriasis, in a subject who has failed or lost response to prior biologic therapy, such as prior administration of etanercept. The invention further provides methods for determining the efficacy of a human TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of a skin disorder associated with detrimental TNF.alpha. activity, such as psoriasis. |
Inventor(s): | Okun; Martin M. (Libertyville, IL), Hoffman; Rebecca S. (Wilmette, IL), Barker; Jonathan (London, GB) |
Assignee: | AbbVie Biotechnology Ltd (Hamilton, BM) |
Application Number: | 12/859,181 |
Patent Claims: | see list of patent claims |
Details for Patent 9,605,064
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2026-04-10 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2026-04-10 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2026-04-10 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2026-04-10 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |